Categorising hybrid material microfluidic devices by Tom Carvell, Paul Burgoyne, Alasdair R. Fraser, Helen Bridle

Get full text

Editorial: Bringing function to the forefront of cell therapy: how do we demonstrate potency? by Alasdair R. Fraser, Stuart M. Curbishley, Andy Roemhild, Kwong Tsang

Get full text

EBV T-cell immunotherapy generated by peptide selection has enhanced effector functionality compared to LCL stimulation by Rachel S. Cooper, Rachel S. Cooper, Catherine Sutherland, Linda M. Smith, Graeme Cowan, Mark Barnett, Donna Mitchell, Colin McLean, Stuart Imlach, Alan Hayes, Sharon Zahra, Champa Manchanayake, Mark A. Vickers, Mark A. Vickers, Gerry Graham, Neil W. A. McGowan, Marc L. Turner, John D. M. Campbell, John D. M. Campbell, Alasdair R. Fraser, Alasdair R. Fraser

Get full text

Rapid GMP-Compliant Expansion of SARS-CoV-2–Specific T Cells From Convalescent Donors for Use as an Allogeneic Cell Therapy for COVID-19 by Rachel S. Cooper, Alasdair R. Fraser, Linda Smith, Paul Burgoyne, Stuart N. Imlach, Lisa M. Jarvis, David M. Turner, Sharon Zahra, Marc L. Turner, John D. M. Campbell

Get full text

Study protocol: a multicentre, open-label, parallel-group, phase 2, randomised controlled trial of autologous macrophage therapy for liver cirrhosis (MATCH) by Catriona Graham, John F Dillon, Scott Semple, Neil Lachlan, Alasdair R Fraser, Jonathan Andrew Fallowfield, Francesca Moroni, Mark Macmillan, Thomas Manship, Stuart J Forbes, Paul Noel Brennan, Alison Glover, David M Morris, Chloe Pass, Neil W A McGowan, Marc L Turner, John D M Campbell

Get full text